A Study of Re-Treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor.
An Open Label Study to Evaluate the Safety of Re-treatment With MabThera, and Its Effect on Treatment Response, in Patients With Rheumatoid Arthritis Following Inadequate Response to a Single Anti-TNF Agent (Extension Study to ML19070).
Sponsor: Hoffmann-La Roche
A PHASE3 clinical study on Rheumatoid Arthritis, this trial is completed. The trial is conducted by Hoffmann-La Roche and has accumulated 7 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 2 earlier versions
-
Sep 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Sep 2017 [monthly]
Completed PHASE3
First recorded
Jul 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hoffmann-La Roche
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bad Aibling, Germany , Bad Bramstedt, Germany , Berlin, Germany , Bonn, Germany , Cologne, Germany , Cuxhaven, Germany , Donaueschingen, Germany , Dresden, Germany , Erfurt, Germany , Erlangen, Germany and 34 more locations